ClinicalTrials.gg
CompletedNCT00152997Updated Oct 31, 2013

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

A Phase 2 interventional study of Pramipexole 0.125 mg tablets and Pramipexole 0.125 mg tablets Placebo in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 7 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-10-31.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
13th of 17
41 · median 154
Started
2004
with 2 others
Phase 2
2 of 17
none open now
Registered
4th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 13th largest by enrollment, is one of 3 that started in 2004, is one of 2 in phase 2, and was the 4th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

The objective of this trial is to investigate the efficacy and safety of pramipexole (0.125-0.75 mg) orally once daily as compared with placebo for 6 weeks in patients with primary restless legs syndrome (RLS) and to investigate the reliability of the Japanese version of the RLS rating scale by the International Restless Legs Syndrome Study Group (IRLSSG) as a sub-study.

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

According to the essential diagnostic criteria for RLS of NIH and IRLSSG, the following four all criterias must be presented:

  1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in legs
  2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting
  3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
  4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night

    • PLM (during time in bed) index of at least 5 per hour (in the worst affected leg) at Visit 3
    • Total score of RLS severity scale-Japanese version by IRLSSG > 15 at Visit 3
    • At least 1 time per week of RLS symptoms interfering with sleep within the last one month at Visit 1.

Exclusion criteria

Exclusion Criteria:

  1. Pre-menopausal women who meet any one of the following (1) - (3):

    • Pregnant or possibly pregnant
    • In lactation
    • Desire to be pregnant during study period Even when a patient was confirmed not to fall under the criteria above at initiation of study, if the patient is of , pregnancy tests should be performed when possible. If pregnancy test is positive, the product should be discontinued.
  2. Males not using an adequate form of .
  3. Patients who took the neuroleptics within 4 weeks before the screening Visit 1, or neuroleptic-induced akathisia.
  4. Patients who can not stop the treatment with medication or dietary supplements, which could significantly influence RLS symptoms to wash-out at least 14 days before drug administration (refer to Appendix 3 for prohibited medication), e.g. dopaminergic drugs (levodopa or dopamine agonists) or antidopaminergic drugs (neuroleptics or metoclopramide etc.), MAO inhibitors, sympathomimetics, antidepressants, hypnotics, any benzodiazepines, antiepileptics, opioids, clonidine, magnesium, ferrous salts, folic acid, vitamin B12, antihistaminics, lithium, melatonin.
  5. Patients with diabetes mellitus requiring insulin therapy.
  6. Patients with microcytic anemia at investigators discretion.
  7. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical, neurological examination, myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms.
  8. Other sleep disorder, such as, REM sleep behaviour disorder, narcolepsy or sleep apnea syndrome (with AHI >15 at Visit 3, or a history of loud snoring occurring at least 5 nights a week combined with a history of breathing pauses during sleep and excessive daytime sleepiness).
  9. renal disease or creatinine higher than (ULN) at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
41 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Endpoint: Decrease in periodic limb movements during time in bed index (PLMI) in the PSG

Secondary outcomes

  1. Total score of RLS severity scale-J by IRLSSG, Periodic Limb Movements during Sleep Index (PLMSI) in the PSG Periodic Limb Movements during Wakefulness Index (PLMWI) in the PSG Periodic Limb Movements in Sleep with Arousal Index (PLMAI) in the PSG )

07

Study locations

7 sites
  • Boehringer Ingelheim Investigational Site
    Akita, Akita, Japan
  • Boehringer Ingelheim Investigational Site
    Kochi, Kochi, Japan
  • Boehringer Ingelheim Investigational Site
    Kurume, Fukuoka, Japan
  • Boehringer Ingelheim Investigational Site
    Otaru,Hokkaido, Japan
  • Boehringer Ingelheim Investigational Site
    Sakai, Osaka, Japan
  • Boehringer Ingelheim Investigational Site
    Shibuya,Tokyo, Japan
  • Boehringer Ingelheim Investigational Site
    Takatsuki, Osaka, Japan
08

References and documents

Publications

  • Inoue Y, Oka Y, Kagimura T, Kuroda K, Hirata K. Reliability, validity, and responsiveness of the Japanese version of International Restless Legs Syndrome Study Group rating scale for restless legs syndrome in a clinical trial setting. Psychiatry Clin Neurosci. 2013 Sep;67(6):412-9. doi: 10.1111/pcn.12074. Epub 2013 Aug 5. PubMed 23910574 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004 and a primary completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 12, 2005
Start
Aug 2004
Primary completionActual
Dec 2005
Last update
Oct 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00152997
First posted
Sep 12, 2005
Start date
Aug 2004
Primary completion
Dec 2005
Last update
Oct 31, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion